• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quintiles deepens investment in China

Quintiles deepens investment in China

June 18, 2012
CenterWatch Staff

Quintiles has decided to establish a Quintiles regional headquarters for China in Shanghai and to significantly expand lab testing capabilities in China.

“With its burgeoning economy and growing healthcare needs for its 1.3 billion citizens, China exemplifies the opportunities and challenges of the New Health,” said Quintiles executive chairman Dennis Gillings, CBE.  “By broadening our investment and infrastructure here, Quintiles is ready to partner with our biopharma customers as they look to realize China’s potential.”

To provide the infrastructure essential for its growth strategy in China, Quintiles is investing $14 million to establish a new 4,000-square-meter (43,000 square feet) headquarters in Shanghai to serve China and nearby Asian countries.  The office in Feng Lin Science Park is designed to achieve LEED Gold accreditation; it is expected to accommodate more than 450 employees in the next five years.

Quintiles will also engage the Shanghai Clinical Research Centre (SCRC) to provide lab testing services to local customers.

“Quintiles recognizes the unique needs of our customers in China. By collaborating with SCRC in labs we can help local and international biopharma companies develop new and better medicines to serve China’s enormous unmet medical needs,” said Ling Zhen, general manager for Quintiles’ operations in China.

The Quintiles-SCRC collaboration follows last year’s launch of Kun Tuo, Quintiles’ local CRO, built to help local and global biopharma companies achieve successful registration of medicines in China.  Quintiles commenced operations in China in 1997, and today has offices in Beijing, Dalian, Hong Kong and Shanghai, with employees and capabilities to serve all major population centers and study sites across China.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing